Andreas Nabers

Bochum, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years.

Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: February 25, 2022

Aβ misfolding in blood plasma is inversely associated with body mass index even in middle adulthood.

Aβ misfolding in blood plasma is inversely associated with body mass index even in middle adulthood.

Journal: Alzheimer's research & therapy

Published: February 17, 2021

Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.

Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.

Journal: Alzheimer's research & therapy

Published: January 16, 2021

Genetic predisposition, Aβ misfolding in blood plasma, and Alzheimer's disease.

Genetic predisposition, Aβ misfolding in blood plasma, and Alzheimer's disease.

Journal: Translational psychiatry

Published: November 16, 2020

Aβ misfolding in blood plasma measured by immuno-infrared-sensor as an age-independent risk marker of Alzheimer's disease.

Aβ misfolding in blood plasma measured by immuno-infrared-sensor as an age-independent risk marker of Alzheimer's disease.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: November 09, 2020

Label-free vibrational imaging of different Aβ plaque types in Alzheimer's disease reveals sequential events in plaque development.

Label-free vibrational imaging of different Aβ plaque types in Alzheimer's disease reveals sequential events in plaque development.

Journal: Acta neuropathologica communications

Published: October 08, 2020

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.

Journal: Alzheimer's research & therapy

Published: August 06, 2020

TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis.

TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis.

Journal: Annals of clinical and translational neurology

Published: July 23, 2020

The Effect of (-)-Epigallocatechin-3-Gallate on the Amyloid-β Secondary Structure.

The Effect of (-)-Epigallocatechin-3-Gallate on the Amyloid-β Secondary Structure.

Journal: Biophysical journal

Published: October 28, 2019

Prediction of Alzheimer's disease diagnosis within 14 years through Aβ misfolding in blood plasma compared to APOE4 status, and other risk factors.

Prediction of Alzheimer's disease diagnosis within 14 years through Aβ misfolding in blood plasma compared to APOE4 status, and other risk factors.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: October 16, 2019

Reversible Immuno-Infrared Sensor for the Detection of Alzheimer's Disease Related Biomarkers.

Reversible Immuno-Infrared Sensor for the Detection of Alzheimer's Disease Related Biomarkers.

Journal: ACS sensors

Published: June 27, 2019

Aβ and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease.

Aβ and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: March 27, 2019

Showing 1-12 of 16

Last Updated: 09/26/2026